Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 10/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274909 | 0.92 | POLB (0.61) | FKBP1APOLBMEN1KMT2ASPHK1 | |
| SCHEMBL2274911 | 0.92 | POLB (0.61) | FKBP1APOLBMEN1KMT2ASPHK1 | |
| SCHEMBL2769755 | 0.87 | MEN1 (0.64) | POLBMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6487168 | 0.86 | FKBP1A (0.55) | FKBP1AKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL2771565 | 0.85 | MEN1 (0.53) | FKBP1APOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2768950 | 0.84 | FKBP1A (0.54) | FKBP1APOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL5520151 | 0.83 | FKBP1A (0.48) | FKBP1APOLBSPHK1 | |
| SCHEMBL28879461 | 0.83 | FKBP1A (0.48) | FKBP1APOLBSPHK1 | |
| SCHEMBL21869793 | 0.83 | POLB (0.58) | FKBP1APOLBMEN1KMT2ASPHK1 | |
| SCHEMBL22608603 | 0.82 | FKBP1A (0.53) | FKBP1APOLBSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107892684-B | Quinazoline derivatives, pharmaceutical compositions thereof, and use as medicaments | 锦州奥鸿药业有限责任公司 | 2020-05-26 | — | — | CN | disclosed |
| EP-3022186-B1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2020-02-26 | — | — | EP | disclosed |
| EP-3022186-B1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2020-02-26 | — | — | EP | disclosed |
| US-10053449-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2018-08-21 | — | — | US | disclosed |
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-9714235-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-9714235-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-9714235-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| EP-3022186-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | Shanghai Fochon Pharmaceutical Co. Ltd (CN) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015007219-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015007219-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014011863-A1 | METHOD OF TREATMENT WITH 3-CYCLOPROPYLCARBONYL-3,6-DIAZABICYCLO[3.1.1]HEPTANE | TARGACEPT, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2012125518-A1 | SALT FORMS OF 3 - CYCLOPROPYLCARBONYL - 3, 6 - DIAZABICYCLO [3.1.1] HEPTANE | TARGACEPT, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| EP-1057894-B1 | Esterase genes and uses of the same | SUMITOMO CHEMICAL CO (JP) | 2010-04-28 | — | — | EP | disclosed |
| US-6506907-B1 | Catalytic reaction of 2-bromo-4-chlorobutyrate with benzylamine to form N-benzylazetidine-2-carboxylic acid ester; cyclization, amination | ASTRAZENECA AB (SE) | 2003-01-14 | — | — | US | disclosed |
| EP-1181273-A1 | NEW PROCESS | AstraZeneca AB (SE) | 2002-02-27 | — | — | EP | disclosed |
| EP-1057894-A2 | Esterase genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-06 | — | — | EP | disclosed |
| WO-2000068193-A1 | NEW PROCESS | ASTRAZENECA AB (SE) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | ABL1, MAP4K2, DMPK | FKBP1A 3102/4885POLB 3516/4885MEN1 2681/4885 |
| US-10053449-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | ABL1, MAP4K2, DMPK | FKBP1A 3102/4885POLB 3516/4885MEN1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.